US EditionMeril’s Myval Devices for TAVR Evaluated at 1 Year in LANDMARK RCT - Cardiac Interventions Today
Summary by Cardiac Interventions Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Meril’s Myval Devices for TAVR Evaluated at 1 Year in LANDMARK RCT - Cardiac Interventions Today
May 29, 2025—Meril Life Sciences recently announced 1-year results from its LANDMARK pivotal trial of its series of Myval transcatheter heart valves (THVs) for transcatheter aortic valve replacement (TAVR). The company stated that the randomized, noninferiority trial is comparing the company’s series of balloon-expandable Myval THVs with contemporary TAVR device series—balloon-expandable Sapien TAVR systems (Edwards Lifesciences) and self-expand…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
